| Anticoagulation and inhibition of nitric oxide synthase influence hepatic hypoxia after monocrotaline exposure. | Toxicology | 2006 Aug 15 | 16828949 |
| Treatment of cancer-associated thrombosis: distinguishing among antithromboticagents. | Semin Oncol | 2006 Apr | 16638458 |
| Fenugreek | | 2006 | 30000838 |
| Anticoagulation: new challenges, old drugs. | Curr Cardiol Rep | 2005 Sep | 16105491 |
| An adverse interaction between warfarin and fluoropyrimidines revisited. | Clin Colorectal Cancer | 2005 Sep | 16197620 |
| Pharmacokinetics of telithromycin: application to dosing in the treatment ofcommunity-acquired respiratory tract infections. | Curr Med Res Opin | 2005 Oct | 16238904 |
| Considerations and challenges with existing treatments for thrombosis in cancerpatients. | Am J Health Syst Pharm | 2005 Nov 15 | 16286367 |
| A better way to prevent blood clots? A drug derived from cobra venom offers an alternative to warfarin, although liver problems temper its benefits. | Harv Heart Lett | 2005 May | 15898148 |
| Efficacy and tolerability of the switch from a branded to a generic warfarinsodium product: an observer-blinded, randomized, crossover study. | Clin Ther | 2005 Mar | 15878384 |
| Influence of vitamin K on anticoagulant therapy depends on vitamin K status andthe source and chemical forms of vitamin K. | Nutr Rev | 2005 Mar | 15825811 |